Please note: Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.
Sphingosine 1-phosphate (S1P) receptor modulators have been the subject of significant interest since the emergence of FTY720 (fingolimod, 1) as the world's first FDA approved oral treatment for relapsing-remitting multiple sclerosis. 1 S1P receptors are G protein-coupled receptors expressed in a variety of tissues and cover a broad range of different physiological functions including lymphocyte trafficking. 2 Sphingosine is phosphorylated by sphingosine kinase to form the natural S1P receptor ligand sphingosine 1-phosphate. 3 1 is phosphorylated similarly to fingolimod-phosphate (1-P) by sphingosine kinase. 4 Agonism of the S1P1 receptor by 1-P induces sequestration of T-cells in the lymphocytes and thereby reduces the infiltration of lymphocytes into the central nervous system. 5 Achieving a high level of S1P1 selectivity for novel S1P receptor modulators has been the focus for a number of academic and industrial groups. 6,7,8 1-P is reported to have comparable affinities to the S1P1 and S1P3 receptors (Table 1) and it is the agonism of the S1P3 receptor which has been attributed to some of FTY720's unwanted side effects such as bradycardia and hypertension. 1, 2 Benzyl ether derivatives 2a-P and 2b-P previously published by Tsuji et al were reported to have far greater S1P1 selectivity than 1-P with EC50 values for S1P3 significantly higher than for S1P1 (Table 1) . 9 However, the analogues reported as being the most S1P1-selective such as 2b-P were found to be poorly phosphorylated by kinases in rat blood and were not progressed. phosphates (1-P, 2a-P and 2b-P). 9 Phosphoramidate (ProTide) technology is a phosphate delivery technology which is typically applied to nucleosides. 10, 11 Often the rate-limiting step of nucleoside activation is phosphorylation by kinases and therefore phosphoramidate technology is applied to nucleosides to bypass the ratelimiting step. 12 ProTide technology masks the charges of the phosphate motif and increases the lipophilicity of the nucleoside and aids passive diffusion of the compound across the cell membrane. 13 Once inside the cell ProTide nucleosides have been found to be processed to the monophosphate by enzymes such as cathepsin A and Hint. 13, 14, 15 Table 1 . In vitro agonist-evoked GTPγS binding of phosphates of FTY720 (1-P) and benzyl ether derivatives 2a-P and 2b-P to human S1P1 snd S1P3 as reported by Tsuji et al. 9 Compound γGTP EC50 (nM) Selectivity S1P1 S1P3 (S1P3 / S1P1) was attempted and successfully achieved. The aim was then to synthesise phosphoramidate analogues and determine using in vitro testing whether ProTide BED analogues can be processed to the pharmacologically active monophosphate.
The synthesis of benzyl ether derivatives 2a and 2b was successfully achieved by carefully following the reported experimental procedures in the original paper 9 and a number of other sources. [16] [17] [18] [19] [20] [21] [22] Some minor modifications to the synthetic procedure previously reported by Tsuji et al were made. The most significant alterations to the reported synthetic procedure were made to the synthesis of 2b. The synthesis of the compounds in the early stages of the total synthesis (compounds 4 -7) were developed using experimental procedures from a number of sources and repeated experimentation was required in order to synthesise the desired compounds with acceptable yields.
An amalgamation of synthetic procedures found in three papers 9,16,17 was eventually developed to yield 4 in acceptable yields (>80%). The synthesis of the 5 was eventually tuned after a similar process of experimentation and a combination of different experimental procedures from different papers. 9,17,18 Notably a Dean Stark trap was used for the synthesis of 4 and 5. The synthesis of 6 also underwent a number of variations and the final procedure was also devised from a combination of procedures from different papers 9, 19, 20 and fine tuning of the experimental
technique. An unusual quirk of the synthesis, as shown in scheme 1, is that if the reaction is done at -78 °C the whole mixture congeals and forms a hard solid but if the mixture is kept at -74 °C the reaction is effective. At temperatures much warmer than -74 °C the yield is compromised.
Achieving this delicate balance in temperature was accomplished by simply conducting the reaction in a dry ice bath with no added acetone. Synthesis of 7 underwent fewer variations than the preceding three compounds. The synthesis was developed principally using two papers. 9, 20 The key modifications made to the original procedure devised were an increase in temperature to 45
°C from room temperature, addition of toluene to the reaction mixture and the use of LiCl and KBH4
as opposed to the more moisture sensitive LiBH4.
Once achieving satisfactory yields of 4, 5, 6, and 7 was attained the rest of the synthetic process for the synthesis of 2a was more straightforward to accomplish as the later stages are detailed in the experimental section of the lead paper. 9 The final 2a compound synthesised was analysed using = 0.5) suggesting that the enantioselective chirality of the starting amino acid ester was retained and the final product is not a 50/50 racemic mixture.
The synthesis of 2b was done in a different manner to that reported in the original paper. 9
Originally 1-bromo-4-(bromomethyl)-2,5-dimethylbenzene as opposed to 8 was synthesised 21 but a complication was encountered in the synthesis of 2b when coupling with 9 was unsuccessfully attempted. It has been suggested that the butyl lithium reagent successfully used in the synthesis of 2a deprotonates the adjacent ortho methyl group on the bromo benzene ring. As iodine has been reported as being a much more reactive leaving group than bromine in Weinreb amide coupling reactions, 22 the synthesis of 1-iodo-4-(bromomethyl)-2,5-dimethylbenzene was attempted (scheme 2). Using a reported synthetic strategy as a basis for trying an alternative isopropylmagnesium chloride base for the Weinreb amide coupling step (step b in scheme 4)
proved to be an effective way of forming the bond. 22 Some alterations were made to the final stages of the synthesis of 2a and 2b. The final two steps (as shown in steps c and d in scheme 4) are reported in the same experimental procedure and no column is reportedly used to purify the product. 9 These stages were conducted separately and a column was used. An acid stability experiment was conducted involving 16 in pH 1.5 buffer over 13 h. 25 There was no discernable change over 13 hours at pH 1.5 suggesting that ProTide BED analogues are able to withstand the acidic conditions of the stomach. 25, 26 Other phosphoramidate benzyl ether derivative analogues tested follow the same profile of stability in acidic and basic conditions. 
Carboxypeptidase Y Processing
A carboxypeptidase Y processing experiment of 16 was conducted following a previously reported experimental procedure. 12 Carboxypeptidase Y is used as a model for native enzymes in the human body such as Cathepsine A 27 which initiates phosphoramidate processing in vivo. Processing was slow as the experiment was conducted over two weeks as opposed to the expected timescale of minutes or hours. After two weeks the reaction mixture was filtered and subjected to mass spectrometric analysis and unexpectedly a mass corresponding to the pharmacologically active monophosphate was detected. The complete processing to the monophosphate was unexpected, as carboxypeptidase has not been previously reported as being capable of fully processing phosphoramidates to the monophosphate. The complete processing to the monophosphate is perhaps due to a chemical difference of the benzyl ether derivatives when compared with nucleosides. The adjacent amine group may be responsible for the processing from the intermediate shown in figure 5 to the monophosphate and may also contribute to the atypical processing speed when compared to previously reported phosphoramidates of nucleosides. 12 It was considered that the unusually slow processing rate was perhaps due to the fact that the experiment was conducted at ambient temperature as opposed to 37 °C, however, a repetition of the experiment conducted at 37 °C gave comparable results. 
Stability in Human Serum
A stability study of 16 in human serum was also conducted following a previously reported procedure. 12 The primary product was the therapeutically relevant monophosphate confirmed by mass spectrometry by analysing the reaction mixture after 12 h and using 31 
Syntheses

Standard procedure for phosphorochloridate synthesis
To a stirred solution of the appropriate amino acid ester salt (1 eq) and the appropriate aryl dichlorophosphate (1 eq) in anhydrous DCM was added dropwise at -78 C anhydrous Et3N (2 eq).
Following the addition, the reaction mixture was stirred at -78 C for 30 min and then at room temperature for 1 h. Formation of the desired compound was monitored by 31 
(2S)-methyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) propoxy) (phenoxy) phosphoryl) amino) propanoate (16)
Compound 16 
(2S)-benzyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) propoxy) (phenoxy) phosphoryl) amino) propanoate (17)
Compound 17 
(2S)-isopropyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) propoxy)(phenoxy) phosphoryl) amino) propanoate (18)
Compound 18 
(2S)-methyl 2-((((R)-2-amino-3-((2,5-dimethyl-4-(4-(p-tolyl) butanoyl) benzyl) oxy)-2-methylpropoxy) (phenoxy) phosphoryl) amino) propanoate (19)
Compound 19 
(2S)-benzyl 2-((((R)-2-amino-3-((2,5-dimethyl-4-(4-(p-tolyl) butanoyl) benzyl) oxy)-2-methylpropoxy) (phenoxy) phosphoryl) amino) propanoate (20)
Compound 20 
Assays
Cell lysate assay
The experiment was carried out by dissolving phosphoramidate test compound (5 mg) in acetoned6 (0.3 ml) and adding 0.1 ml of Trizma buffer (pH 7.6). After the 31 P NMR data were recorded at 25 C as a control, 0.125 ml cell lysate and 0.02 ml activator was added to the sample. Next, the sample was shaken and submitted to 31 P NMR experiments at 37 C and the spectra were recorded every 7 min over 13 h. 31 P NMR recorded data were processed and analysed with the Bruker Topspin 2.1 program. One experiment was performed for each compound tested.
Human serum assay
The experiment was carried out by dissolving test compound in DMSO (0.05 ml) and D2O (0.15 ml). After the 31 P NMR data were recorded at 37 C as a control, a previously defrosted human serum (male AB plasma) (0.3 ml) was added to the sample. Next, the sample was submitted to 31 P NMR experiments at 37 C and the spectra were recorded every 15 min over 13 h. 31 P NMR recorded data were processed and analysed with the Bruker Topspin 2.1 program. One experiment was performed for each compound tested.
Carboxypeptidase Y assay
The experiment was carried out by dissolving phosphoramidate compound (3 mg) in acetone-d6 (0.15 ml) and adding 0.3 ml of Trizma buffer (pH 7.6). After the 31 P NMR data were recorded at 25
C as a control, a previously defrosted carboxypeptidase Y (0.1 mg dissolved in 0.15 ml of Trizma)
was added to the sample. Next, the sample was submitted to 31 P NMR experiments the spectra were recorded every day over 2 weeks. 31 P NMR recorded data were processed and analysed with the Bruker Topspin 2.1 program. 1 Two experiments were performed for each compound tested.
Acid stability
The stability assay toward hydrolysis by aqueous buffer at pH 1.5 was conducted using in situ 31 P NMR (202 MHz). The experiment was carried out by dissolving test compound (3 mg) in methanold4 (0.1 ml) and then adding buffer of pH 1.5 (prepared from HCl and KCl). Next, the sample was subjected to 31 P NMR experiments at 25 C and the spectra were recorded every 12 min over 13 h.
Base stability
The stability assay toward hydrolysis by aqueous buffer at pH 8 was conducted using in situ 31 P NMR (202 MHz). The experiment was carried out by dissolving test compound (3 mg) in methanold4 (0.1 ml) and then adding pH 8 buffer (prepared from tris(hydroxymethyl)aminomethane and HCl). Next, the sample was subjected to 31 P NMR experiments at 25 C and the spectra were recorded every 12 min over 13 h.
Generating cell lysate
J1 ES cell-derived neurons were generated in vitro as previously described. 28 The glutamatergiclike neurons were cultured at a density of 5.4E+5 cells/cm 2 for 2 weeks before the lysis of the neurons. 6 million neurons were lysed in 300 l of lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % Triton, 0.2 % Sodiumdeoxycholate, 10 % Glycerol). Cell lysate was centrifuged at 3000 rpm for 10 min and transferred into a fresh tube. It was stored at -20 °C until further use. To improve enzyme performance MgCl2 and ATP was added in form of a DNA ligation buffer (T4 DNA Ligase Buffer, NEB). 
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